Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2285-2291

  Cozen, Wendy ^a,b,c   Gebregziabher, Mulugeta ^d   Conti, David V ^a   Van Den Berg, David J ^a,b   Coetzee, Gerhard A ^a,b,c   Wang, Sophia S ^e   Rothman, Nathaniel ^e   Bernstein, Leslie ^a,b   Hartge, Patricia ^e   Morhbacher, Ann ^a,b   Coetzee, Simon G ^a,b,c   Salam, Muhammad T ^a   Wang, Wei ^a   Zadnick, John ^a   Ingles, Sue A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OBESITY; PLASMACYTOMA; PRIORITY JOURNAL; PROMOTER REGION; QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 33845360619     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0446     Document Type: Article

References (52)

1. Grogan T, Muller-Hermelink H, Van Camp B, Harris N, Kyle R. Plasma cell neoplasms. In: Jaffe E, Harris N, Stein H, Vardiman J, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC; 2001. p. 142-56.
2. Gebregziabher M, Bernstein L, Wang Y, Cozen W. Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States). Cancer Causes Control 2006;17:931-8.
3. Ogmundsdottir H, Haraldsdottir V, Johannesson G, et al. A familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica 2005;90:66-71.
4. Bourget C, Grufferman S, Delzell E. Multiple myeloma and family history of cancer. A case-control study. Cancer 1985;56:2133-9.
5. Brown L, Linet M, Greenberg R, et al. Multiple myeloma and family history of cancer among Blacks and Whites in the U S. Cancer 1999;85:2385-90.
6. Erikkson M, Hallberg B. Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 1992;3:63-7.
7. Landgren O, Linet M, McMaster M, Gridley G, Hemminki K, Goldin L. Familial clustering of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006;118:3095-8.
8. Klein B, Zhang X-G, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. J Am Society Hematol 1995;85:863-72.
9. Nachbaur D, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol 1991;62:54-8.
10. Reibneggar G, Krainer M, Herold M, Ludwig H, Wachter H, Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991;51:6250-3.
11. Pelliniemi T, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85:765-71.
12. Lauta V. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97:2440-52.
13. Terry C, Loukaci V, Green F. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000;275:18138-44.
14. Villuendas G, San Millan J, Sancho J, Escobar-Morreale H. The -597 G-A and -174 G-C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002;87:1134-41.
15. Rivera-Chavez F, Peters-Hybki D, Barber R, O'Keefe G. Interleukin-6 promotor haplotypes and interleukin-6 cytokine responses. Shock 2003;20:218-23.
16. Dring AM, Davies FE, Rollinson SJ, et al. Interleukin 6, tumour necrosis factor [α] and lymphotoxin [α] polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma. Br J Haematology 2001;112:249-50.
17. Mazur G, Bogunia-Kubik K, Wrobel T, et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 2005;96:241-6.
18. Iakupova E, Grinchuk O, Kalimullina D, et al. Molecular genetic analysis of the interleukin 6 and tumor necrosis factor α gene polymorphisms in multiple myeloma. Mol Biol (Mosk) 2003;37:420-4.
19. Zheng C, Huang D, Bergenbrant S, et al. Interleukin 6, tumour necrosis factor [α], interleukin 1 [β] and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000;109:39-45.
20. Mullberg J, Oberthur W, Lottspeich F, et al. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol 1994;152:4958-68.
21. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-9.
22. Brown L, Gridley G, Pottern L, et al. Diet and nutrition as risk factors for multiple myeloma among Blacks and Whites in the United States. Cancer Causes Control 2001;12:117-25.
23. Friedman G, Herrinton L. Obesity and multiple myeloma. Cancer Causes Control 1994;5:479-83.
24. Pan S, Johnson K, Ugnat A-M, Wen S, Mao Y, CCRER Group, R. Association of obesity and cancer risk in Canada. AJE 2004;159:259-68.
25. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21.
26. Calle E, Rodriguez C, Walker-Thurmond K, Thun M. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U S. adults. N Engl J Med 2003;348:1625-38.
27. Blair C, Cerhan J, Folsom A, Ross J. Anthropometric characteristics and risk of multiple myeloma. Epidemiology 2005;16:691-4.
28. Samanic C, Gridley G, Chow W-H, Lubin J, Hoover R, Fraumeni JJ. Obsesity and cancer risk among White and Black United States veterans. Cancer Causes Control 2004;15:35-43.
29. Wernstedt I, Eriksson A, Berndtsson A, et al. A common polymorphism in the interleukin-6 gene promoter is associated with overweight. Int J Obesity Related Disorders 2004;28:1272-9.
30. Wolford J, Colligan P, Gruber J, Bogardus C. Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Mol Genet Metab 2003;80:338-43.
31. Escobar-Morreale H, Calvo R, Villeundas G, Sancho J, San Millan J. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003;11:987-96.
32. Bhatti P, Sigurdson A, Wang S, et al. Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 2005;14:2449-53.
33. Lee L, Connell C, Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res 1993;21:3761-6.
34. Devlin B, Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 1995;29:311-22.
35. Hosmer D, Lemeshow S. Applied logistic regression. New York (NY): John Wiley & Sons, Inc.; 2000.
36. Breslow N, Day N. Statistical methods in cancer research II: the analysis of case control studies. Lyon (France): IARC Scientific Publications; 1980.
37. Hamid Y, Rose C, Urhammer S, et al. Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 2005;48:251-60.
38. Brull D, Montgomery H, Sanders J, et al. Interleukin-6 gene -174G>C and -572 G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary bypass surgery. Arterioscler Thromb Vasc Biol 2001;21:1458-63.
39. Bennermo M, Held C, Green F, et al. Prognostic value of plasma interleukin-6 concentrations and the -174 G>C and -572 G>C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 2004;174:157-63.
40. Ferrari S, Ahn-Luong L, Garnero P, Humphries S, Greenspan S. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in post-menopausal women. J Clin Endocrinol Metab 2000;88:255-9.
41. Chung H, Seo J, Hur S, et al. Association of interleukin-6 promoter variant with bone mineral density in pre-menopausal women. J Hum Genet 2003;48:243-8.
42. Harding D, Brull D, Humphries S, Whitelaw A, Montgomery H, Marlow N. Variation in the interleukin-6 gene is associated with impared cognitive development in children born prematurely: a preliminary study. Pediatr Res 2005;58:117-20.
43. Komatsu Y, Tai H, Galicia J, et al. Interleukin-6 (IL6) - -373A9T11 allele is associated with reduced susceptibility to periodontitis in Japanese. Tissue Antigens 2005;65:110-4.
44. Wisse B. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.
45. Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Haematology 2000;111:626-34.
46. Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002;100:3925-9.
47. Morimoto LM, NP, Newcomb PA, White E, Bigler J, Potter JD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Biomarkers Prev 2005;14:1394-401.
48. Sun G, Gagnon J, Chagnon Y, et al. Association and linkage between an insulin-like growth factor-1 gene polymorphism and fat free mass in the HERITAGE Family Study. Int J Obesity Related Disorders 1999;23:929-35.
49. Reiner AP, Diehr P, Browner WS, et al. Common promoter polymorphisms of inflammation and thrombosis genes and longevity in older adults: the cardiovascular health study. Atherosclerosis 2005;181:175-83.
50. Hurme M, Lehtimaki T, Jylha M, Karhunen PJ, Hervonen A. Interleukin-6 -174G/C polymorphism and longevity: a follow-up study. Mech Ageing Dev 2005;126:417-8.
51. Capurso C, Solfrizzi V, D'Introno A, et al. Interleukin 6 -174 G/C promoter gene polymorphism in centenarians: no evidence of assocation with human longevity or interaction with apolipoprotein E alleles. Exp Gerontol 2004;39:1109-14.
52. Tan Q, Christiansen L, Bathum L, et al. Estimating haplotype relative risks on human survival in population-based association studies. Hum Hered 2005;59:88-97.